Fig. 3.

Immunomodulation proteins of cAM-MSCs in mice skin as determined by immunostaining. (A, B) (A) Representative confocal image showing canine MSC-positive CD90 cells (red) and nuclei (blue). Scale bars, 200 μm. (B) Quantification of marker CD90-positive cells. n = 3 for each slide, mean ± SD; *** p < 0.001, n.s. not significantly different from control. (C, D) (C) Confocal image showing the immunomodulation marker TGFβ1 (green), CD90-positive canine MSCs (red) and nuclei (blue); scale bars, 200 μm. (D) Quantification of the marker TGFβ1-positive cells. n = 3 for each slide, mean ± SD; * p < 0.05, ** p < 0.01, n.s. not significantly different from the control. (E, F) (E) Confocal image showing the immunomodulation marker COX-2 (green), CD90-positive canine MSCs (red) and nuclei (blue); scale bars, 200 μm. (F) Quantification of COX-2-positive cells. n = 3 for each slide, mean ± SD; *** p < 0.001, n.s., not significantly different versus the control. (G, H) (G) Confocal image showing the immunomodulation marker IDO1 (green) and CD90-positive canine MSCs (red) and nuclei (blue); scale bars, 200 μm. (H) Quantification of marker IDO1-positive cells. n = 3 for each slide, mean ± SD; * p < 0.05, *** p < 0.001, n.s. not significantly different from the control